Oruka Therapeutics, Inc.
orukatx.comWhat Do They Do?
Develops antibody drug candidates for psoriasis and other inflammatory and immune diseases, aimed at treating chronic skin and related conditions.
10-K for FY2025, filed Mar 12, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
−$41.2MView ↗
- ▲ +68% (Loss)
- vs −$24.6M in Q2 FY2025
-
Jun 1, 2026
Expanded IL-23 license to include inflammatory bowel disease
The amendment broadens the license to all therapeutic areas, with timing limits on clinical trials for inflammatory bowel disease.
Sources
8-K, filed Jun 1, 2026
On May 29, 2026, Oruka Therapeutics, Inc. (the “Company”) entered into the First Amendment to IL-23 License Agreement (the “Amendment”)…View ↗
From heart disease to skin disease
The older report centered on precision-targeted cardiovascular therapies, including Gencaro for atrial fibrillation in people with heart failure; the latest centers on antibody candidates for psoriasis and other inflammatory and immune diseases.
10-K for FY2022, filed Feb 24, 2023 10-K for FY2025, filed Mar 12, 2026
Who Do They Compete With?
Competes with AbbVie, Janssen, Sun Pharma, Almirall, Innovent Biologics, UCB, Novartis, Eli Lilly, Ortho Dermatologics, LEO Pharma, Amgen, Bristol-Myers Squibb, MoonLake Immunotherapeutics, Protagonist, Takeda, and Alumis
10-K for FY2025, filed Mar 12, 2026There are several approved biologic therapies for the treatment of moderate-to-severe PsO. These include mAbs targeting IL-23, such as…View ↗
Loading...
